Lista de obras - Giacomo Cartenì - Dominio Público Uruguay

18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report

artículo científico publicado en 2013

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

artículo científico publicado en 2014

Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients

artículo científico publicado en 2009

Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

artículo científico publicado en 2007

Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy ⬇️

artículo científico publicado el 2 de agosto de 2013

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial

artículo científico publicado en 2000

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

artículo científico publicado en 2015

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.

artículo científico publicado en 2011

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

artículo científico publicado en 2014

Clinical management of metastatic kidney cancer: the role of new molecular drugs

artículo científico publicado en 2015

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort

artículo científico publicado en 2013

Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

artículo científico publicado en 2014

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly

artículo científico publicado en 2007

Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients.

artículo científico publicado en 2008

Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial

artículo científico publicado en 2006

Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.

artículo científico publicado en 2014

Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

artículo científico publicado en 2014

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

artículo científico publicado en 2005

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

artículo científico publicado en 2015

Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.

artículo científico publicado en 2013

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

artículo científico publicado en 2006

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung can

artículo científico publicado en 2009

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

artículo científico publicado en 2012

Horner's syndrome: An unusual presentation of metastatic disease in breast cancer

artículo científico publicado en 2015

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study

artículo científico publicado en 2006

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

artículo científico publicado en 2008

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey

artículo científico publicado en 2013

Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?

artículo científico

Pancreatic solitary and synchronous metastasis from breast cancer: a case report and systematic review of controversies in diagnosis and treatment

artículo científico publicado en 2014

Panitumumab a novel drug in cancer treatment.

artículo científico publicado en 2007

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

artículo científico publicado en 2011

Phase II study of rubitecan in recurrent or metastatic head and neck cancer

artículo científico publicado en 2007

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

artículo científico publicado en 2009

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

artículo científico publicado en 2005

Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.

artículo científico

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

artículo científico publicado en 2014

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

artículo científico publicado en 2010

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer

artículo científico publicado en 2013

Real-world study of everolimus in advanced progressive neuroendocrine tumors

artículo científico publicado en 2014

Recent developments in second and third line therapy of metastatic renal cell carcinoma

artículo científico publicado en 2016

Renal cell carcinoma in adult patients with thalassaemia major: a description of three cases

scientific article published on 26 February 2014

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

artículo científico publicado en 2015

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

article

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

artículo científico publicado en 2010

Sunitinib: bridging present and future cancer treatment.

artículo científico publicado en 2007

The ORCHIDEE study: gathering new evidence on the use of everolimus in clinical practice

artículo científico publicado en 2014

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

artículo científico publicado en 2015

The therapy of kidney cancer with biomolecular drugs.

artículo científico publicado en 2010

The treating scenario in genitourinary oncology: what is new? Part 1.

artículo científico publicado en 2013

The treating scenario in genitourinary oncology: what is new? Part 2.

artículo científico publicado en 2013

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

artículo científico publicado en 2004

We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.

artículo científico publicado en 2014

Lista de obras de Giacomo Cartenì

18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients

Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy ⬇️

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

Clinical management of metastatic kidney cancer: the role of new molecular drugs

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort

Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly

Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients.

Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial

Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.

Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung can

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

Horner's syndrome: An unusual presentation of metastatic disease in breast cancer

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey

Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?

Pancreatic solitary and synchronous metastasis from breast cancer: a case report and systematic review of controversies in diagnosis and treatment

Panitumumab a novel drug in cancer treatment.

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

Phase II study of rubitecan in recurrent or metastatic head and neck cancer

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer

Real-world study of everolimus in advanced progressive neuroendocrine tumors

Recent developments in second and third line therapy of metastatic renal cell carcinoma

Renal cell carcinoma in adult patients with thalassaemia major: a description of three cases

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

Sunitinib: bridging present and future cancer treatment.

The ORCHIDEE study: gathering new evidence on the use of everolimus in clinical practice

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

The therapy of kidney cancer with biomolecular drugs.

The treating scenario in genitourinary oncology: what is new? Part 1.

The treating scenario in genitourinary oncology: what is new? Part 2.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.